A van der Veen1, M F J Seesing1, B P L Wijnhoven2, W O de Steur3, M I van Berge Henegouwen4, C Rosman5, J W van Sandick6, S Mook7, N Haj Mohammad8, J P Ruurda1, L A A Brosens9, R van Hillegersberg10. 1. Department of Surgical Oncology, University Medical Center Utrecht, The Netherlands. 2. Department of Surgical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands. 3. Department of Surgical Oncology, Leiden University Medical Center, The Netherlands. 4. Department of Surgery, Academic Medical Center and Cancer Center Amsterdam, Amsterdam, The Netherlands. 5. Department of Surgery, Radboud University Medical Center, Nijmegen, The Netherlands. 6. Department of Surgery, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. 7. Department of Radiation Oncology, University Medical Center Utrecht, The Netherlands. 8. Department of Medical Oncology, University Medical Center Utrecht, The Netherlands. 9. Department of Pathology, University Medical Center Utrecht, The Netherlands. 10. Department of Surgical Oncology, University Medical Center Utrecht, The Netherlands. Electronic address: r.vanhillegersberg@umcutrecht.nl.
Abstract
INTRODUCTION: The aim of this study is to provide insight in accuracy of diagnosing, current treatment and survival in patients with resectable esophageal and gastric neuroendocrine- and mixed adenoneuroendocrine carcinomas (NEC, MANEC). METHODS: All patients with esophageal or gastric (MA)NEC, who underwent surgical resection between 2006 and 2016, were identified from the Dutch national registry for histo- and cytopathology (PALGA). Patients with a neuroendocrine tumor lower than grade 3 were excluded. Data on patients, treatment and outcomes were retrieved from the patient records. Diagnosis by endoscopic biopsy was compared with diagnosis by resection specimen. Kaplan Meier survival analysis was performed. RESULTS: A total of 49 patients were identified in 25 hospitals, including 21 patients with esophageal (MA)NEC and 26 patients with gastric (MA)NEC on resection specimen. Biopsy diagnosis of (MA)NEC was correct in 23/27 patients. However, 20/47 patients with definitive diagnosis of (MA)NEC, were misdiagnosed on biopsy. Neoadjuvant therapy was administered in 13 (62%) esophageal (MA)NECs and 12 (46%) gastric (MA)NECs. Survival curves were similar with and without neoadjuvant therapy. One (4.8%) esophageal (MA)NEC and 4 (15%) gastric (MA)NECs died within 90 days postoperatively. For esophageal (MA)NEC the median overall survival (OS) after surgery was 37 months and 1-, 3- and 5-year OS were 71%, 50% and 35%, respectively. For gastric (MA)NEC, the median OS was 23 months and 1-, 3- and 5-year OS were 62%, 50% and 39%, respectively. CONCLUSION: Localized esophageal and gastric (MA)NEC are often misdiagnosed on endoscopic biopsies. After resection, long-term survival was achieved in respectively 35% and 39% of patients.
INTRODUCTION: The aim of this study is to provide insight in accuracy of diagnosing, current treatment and survival in patients with resectable esophageal and gastric neuroendocrine- and mixed adenoneuroendocrine carcinomas (NEC, MANEC). METHODS: All patients with esophageal or gastric (MA)NEC, who underwent surgical resection between 2006 and 2016, were identified from the Dutch national registry for histo- and cytopathology (PALGA). Patients with a neuroendocrine tumor lower than grade 3 were excluded. Data on patients, treatment and outcomes were retrieved from the patient records. Diagnosis by endoscopic biopsy was compared with diagnosis by resection specimen. Kaplan Meier survival analysis was performed. RESULTS: A total of 49 patients were identified in 25 hospitals, including 21 patients with esophageal (MA)NEC and 26 patients with gastric (MA)NEC on resection specimen. Biopsy diagnosis of (MA)NEC was correct in 23/27 patients. However, 20/47 patients with definitive diagnosis of (MA)NEC, were misdiagnosed on biopsy. Neoadjuvant therapy was administered in 13 (62%) esophageal (MA)NECs and 12 (46%) gastric (MA)NECs. Survival curves were similar with and without neoadjuvant therapy. One (4.8%) esophageal (MA)NEC and 4 (15%) gastric (MA)NECs died within 90 days postoperatively. For esophageal (MA)NEC the median overall survival (OS) after surgery was 37 months and 1-, 3- and 5-year OS were 71%, 50% and 35%, respectively. For gastric (MA)NEC, the median OS was 23 months and 1-, 3- and 5-year OS were 62%, 50% and 39%, respectively. CONCLUSION: Localized esophageal and gastric (MA)NEC are often misdiagnosed on endoscopic biopsies. After resection, long-term survival was achieved in respectively 35% and 39% of patients.
Authors: Marcus Fernando Kodama Pertille Ramos; Marina Alessandra Pereira; Arthur Youssif Mota Arabi; Melissa Mello Mazepa; Andre Roncon Dias; Ulysses Ribeiro; Bruno Zilberstein; Sergio Carlos Nahas Journal: Med Sci (Basel) Date: 2021-06-25
Authors: Melissa Frizziero; Bipasha Chakrabarty; Bence Nagy; Angela Lamarca; Richard A Hubner; Juan W Valle; Mairéad G McNamara Journal: J Clin Med Date: 2020-01-19 Impact factor: 4.241
Authors: Alicia S Borggreve; Sophie E Heethuis; Mick R Boekhoff; Lucas Goense; Peter S N van Rossum; Lodewijk A A Brosens; Astrid L H M W van Lier; Richard van Hillegersberg; Jan J W Lagendijk; Stella Mook; Jelle P Ruurda; Gert J Meijer Journal: Eur Radiol Date: 2019-12-10 Impact factor: 5.315